Key result
The 2017 ACC/AHA guidelines recommend lifestyle measures plus BP-lowering drugs for secondary prevention in persons with clinical cardiovascular disease and an average BP ≥130/80 mmHg.
This review summarizes the 2017 ACC/AHA hypertension guidelines, which recommend lower blood pressure thresholds for treatment initiation based on cardiovascular risk.
Alerts clinicians to 2017 BP thresholds in secondary CVD prevention; leaves open prospective outcome validation.
Automated validated devices should be used for measuring blood pressure (BP). The 2017 American College of Cardiology (ACC)/American Heart Association (AHA) hypertension guidelines recommend that a systolic BP between 120-129 mmHg with a diastolic BP less than 80 mmHg should be treated with lifestyle measures. These guidelines recommend treatment with lifestyle measures plus BP lowering drugs for secondary prevention of cardiovascular events in persons with clinical cardiovascular disease and an average systolic BP of ≥130 mmHg or an average diastolic BP≥80 mmHg. These guidelines recommend treatment with lifestyle measures plus BP lowering drugs for primary prevention of cardiovascular disease in persons with an estimated 10-year risk of atherosclerotic cardiovascular disease ≥ 10% and an average systolic BP ≥130 mmHg or an average diastolic BP ≥80 mmHg. These guidelines recommend treatment with lifestyle measures plus BP lowering drugs for primary prevention of cardiovascular disease in persons with an estimated 10-year risk of atherosclerotic cardiovascular disease of < 10% and an average systolic BP ≥140 mmHg or an average diastolic BP ≥ 90 mmHg. These guidelines recommend initiating antihypertensive drug therapy with 2 first-line drugs from different classes either as separate agents or in a fixed-dose combination in persons with a BP ≥140/90 mmHg or with a BP > 20/10 mmHg above their BP target. White coat hypertension must be excluded before starting treatment with antihypertensive drugs in persons with hypertension at low risk for atherosclerotic cardiovascular disease. Antihypertensive drug treatment for different disorders is discussed.
No takes yet. Share an insight, caveat, or question.
Wilbert S. Aronow (2019) conducted a review in Hypertension. 2017 ACC/AHA Hypertension Guidelines was evaluated. The 2017 ACC/AHA guidelines recommend lifestyle measures plus BP-lowering drugs for secondary prevention in persons with clinical cardiovascular disease and an average BP ≥130/80 mmHg.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: